Provider Authorization

This clinical prescription is restricted. Please enter the referral code provided by your clinician to access this formulation.

Invalid or expired code. Please try again.
Request Access
← Return to catalog
Tirzepatide
Treatment

Tirzepatide.a dual GLP-1 / GIP receptor agonist

★★★★★ 4.9
$—
Vial size 5MG (0.5MG/ML)
Pack size 1 vial (2ML)
Date of birth
Quantity
Ships 1–2 business days after approval
ClassDual GLP-1 / GIP agonistDual GLP-1 / GIP agonist.
Mol. weight4813.45 DaConfirmed on every batch shipped.
Half-life5 daysOnce-weekly dosing target.
—
Tirzepatide
✓ Added 1× Tirzepatide View cart →
— Mechanism / 01

Two receptors. Steeper curve than sema.

Compounded tirzepatide acts on both GLP-1 and GIP receptors. Prescribed only after a review by a US-licensed clinician. The bridge molecule between sema-era dosing.

GLP-1 receptor

Same appetite, gastric, and insulin levers as semaglutide — the foundation of the response.

Effect · Primary
— Reference prescription / 02

Titration schedule.

Your clinician sets and adjusts your dose.

Weeks 1–42.5 mg

Onboarding. Starting dose set by your clinician.

Weeks 5–85.0 mg

First step-up. Many cruise here long-term.

Weeks 9–127.5–10 mg

Mid-prescription.

Weeks 13+10–15 mg

Maintenance dose. The 15mg arm produced the steepest GIP-era curve.

— Common questions / 05

Before you order.

Tirz vs Sema?
Tirz adds GIP — that's a steeper curve and (in many) softer GI. Sema has more years of data.
Independent COA?
Every batch tested.
How do I cancel a subscription?
From your account dashboard, in two clicks. No retention call, no email loop. Pause, skip, or cancel any time before the next ship date.

Important Safety Information

Before using this medication, review these safety guidelines. The specific medical text, full side effect profile, and patient counseling materials must be provided and reviewed by your prescribing clinician or dispensing pharmacy prior to treatment.

Contraindications & Warnings:
Do not use this medication if you have a known allergy to it or any of its ingredients.
Risk of Thyroid Tumors:
GLP-1 receptor agonist medications, such as semaglutide and tirzepatide, carry a boxed warning regarding the risk of thyroid C-cell tumors. Do not use these medications if you or anyone in your family has ever had Medullary Thyroid Carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Serious Risks:
Serious but rare side effects can occur. Please consult the full prescribing information for risks related to pancreatitis, gallbladder problems, kidney injury, low blood sugar (hypoglycemia), serious allergic reactions, and changes in vision.
Common Side Effects:
he most common side effects include mild-to-moderate nausea, vomiting, diarrhea, constipation, and stomach pain. These often improve over time.